Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
|Videos|November 16, 2022
Captisol- Why it’s the UNRIVALED Modified Cyclodextrin
Author(s)Ligand
Key Learning Objectives
- Captisol is in over a dozen FDA approved products with multiple product approvals coming in the next year. These approvals include oral and ophthalmic routes of administration. Proven safe!
- A team of experts with 20+ years of experience who are ready to answer any questions are what sets Captisol apart from other modified cyclodextrins.
- Ligand formulation services are now available to assist with consideration of CAPTISOL for solving product development issues and achieving Target Product Profile goals
Related to this article
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
Trending on Pharmaceutical Technology
1
Germany’s Medical Biotechnology Sector is Flourishing
2
Formulation Strategies for Next-Generation Multiagonists
3
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
4
First-in-Human Trial Speed: Why FDA Trails China
5